Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phlebotomy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Phlebotomy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-005259-18 Sponsor Protocol Number: PROUD-PV Start Date*: 2013-08-15
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001672-38 Sponsor Protocol Number: KRT-232-102 Start Date*: 2018-12-10
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi...
    Medical condition: Phlebotomy-dependent polycythemia vera. Polycythemia Vera (PV) is classified as a myeloproliferative neoplasm (MPN).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002529-12 Sponsor Protocol Number: CICL670F2203 Start Date*: 2017-10-19
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012236 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003583-31 Sponsor Protocol Number: CINC424B2401 Start Date*: 2014-02-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant...
    Medical condition: Polycythemia vera resistant or intolerant to hydroxyurea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003598-33 Sponsor Protocol Number: LJ401-HH01 Start Date*: 2018-04-03
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Phase 2, Multi-center, Randomized, Placebo-controlled, Single-blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003704-40 Sponsor Protocol Number: ISIS702843-CS4 Start Date*: 2023-02-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Pol...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002132-25 Sponsor Protocol Number: 12-181 Start Date*: 2015-06-29
    Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty
    Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial
    Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006694-91 Sponsor Protocol Number: FARM6YNXAN Start Date*: 2008-05-23
    Sponsor Name:G.I.M.E.M.A.
    Full Title: A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV) – CYTO-PV.
    Medical condition: Polycytemia vera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028576 Myeloproliferative disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020807-57 Sponsor Protocol Number: CINC424B2301 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ...
    Medical condition: Polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002318-37 Sponsor Protocol Number: INCB18424-357 Start Date*: 2012-11-06
    Sponsor Name:Incyte Corporation
    Full Title: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
    Medical condition: Polycythemia Vera
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000861-58 Sponsor Protocol Number: NP39761 Start Date*: 2019-10-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PARTICIPANTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POL...
    Medical condition: Polycythemia Vera (PV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001357-17 Sponsor Protocol Number: CONTINUATION-PV Start Date*: 2014-11-03
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) PL (Completed) SK (Completed) BG (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004732-29 Sponsor Protocol Number: PTG-300-11 Start Date*: 2022-06-21
    Sponsor Name:Protagonist Therapeutics, Inc.
    Full Title: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000603-32 Sponsor Protocol Number: NL3364409612 Start Date*: 2012-08-27
    Sponsor Name:Annadalstichting
    Full Title: Proton pump inhibitors in the prevention of iron reaccumulation in patients with hereditary hemochromatosis
    Medical condition: Hereditary hemochromatosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001847-58 Sponsor Protocol Number: ARD12042 Start Date*: 2011-10-12
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or in...
    Medical condition: polycythemia vera, or essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007335-99 Sponsor Protocol Number: Tarceva-HH-2008 Start Date*: 2009-08-24
    Sponsor Name:Herlev Hospital, Dept. of Haematology (L121)
    Full Title: A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia
    Medical condition: Polycythaemia Vera & Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015494 Essential thrombocythemia LLT
    9.1 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005197-38 Sponsor Protocol Number: TD9707-LT Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: Six-Month, One-Year, Three-Year, Five-Year and Ten-Year Data on the Long-Term Immunogenicity of Td-mIPV, Tdap-vIPV, Td, aP and Tdap in Adolescents and Adults
    Medical condition: Pertussis Tetanus Diphtheria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002099-16 Sponsor Protocol Number: 06/Q0703/56 Start Date*: 2006-07-13
    Sponsor Name:King's College London
    Full Title: The effect of milk thistle extract (Legalon) versus tea on serum iron increase after a meal containing non-haem iron in hereditary haemochromatosis
    Medical condition: Type 1 hereditary haemochromatosis is associated with homozygous inheritance of the C282Y mutation in the HFE gene. The phenotype is characterised by increased serum iron levels, tissue iron accumu...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057873 Hereditary haemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001919-31 Sponsor Protocol Number: DALIAH Start Date*: 2011-09-12
    Sponsor Name:Roskilde sygehus
    Full Title: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy,...
    Medical condition: Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005306-49 Sponsor Protocol Number: MK-0683-092 Start Date*: 2008-09-03
    Sponsor Name:Department of Haematology, Herlev Hospital, University of Copenhagen
    Full Title: A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia
    Medical condition: patients with polycythaemia vera or essential thrombocythaemia or myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    9.1 10015493 Essential thrombocythaemia LLT
    12.1 10028537 Myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 08:22:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA